The Pharma Files: What Have you Missed?
As you probably know, Evaluate has an incredibly rich and comprehensive set of data and insight about the pharma market. This means we’re able to produce some really valuable reports, webinars and articles that provide insight around the most exciting areas of the industry. And we create rather a lot of them, which can make […]
Is it Time to Rethink Orphan Drugs?
If you follow Evaluate’s regular white papers and blogs, you may be familiar with our annual report that investigates the state of the orphan drug market. I’ve been involved in analyzing that data for the past three years, and have just finished the process for this year’s report which will be published soon. One of […]
How Pharma Professionals Rate Our Forecasting Training
Formal training is essential for stakeholder teams looking to enhance their forecasting expertise. By deepening their understanding of fundamental principles, methodologies, and process steps, teams can approach forecasting with greater confidence and ensure they are applying best practices effectively. However, learning should not be a passive process. We believe self-assessment is a powerful tool for […]
Three Things we Learned in our Long-Range Planning Webinar
How’s your long-range planning going? If you’re tasked with the forecasting processes for a pharma or biotech company, you may be in the midst of this annual cycle at the moment. Long-range planning (or LRP as the cool forecasters call it) provides a really important guide to company performance over five to 10 years. Like […]
Three Things we Learned in our 2025 Preview Webinar
The first Evaluate webinar of the year is in the bag. Based on our 2025 Preview report, this session brought together three of our industry experts to discuss what the year ahead might hold for pharma. They may not have had a crystal ball, but they had plenty of detailed data and insight which is […]
What Will 2025 Hold for Pharma?
Once again, the pharma industry starts a new year with hopes of a recovery. Will 2025 finally see a return of IPOs? Of mega-mergers? Of huge rounds of investment? Perhaps, but more likely this year will simply be a few steps in the right direction. There is still a great deal of uncertainty, particularly around […]
Biopharma Reading List: The Evaluate Top 10 of 2024
Obesity. The Inflation Reduction Act. Orphan Drugs. CDMOs. Successful forecasting techniques. We’ve covered all this and more in our biopharma reports, webinars and analysis throughout 2024. As I’ve had the pleasure of working with our experts to create all this content, I thought year-end was a splendid opportunity to share the most-read pieces of the […]
Three Things we Learned in our Launch Excellence Webinar
Picture the scene. You’ve got a new, hugely promising new drug in the pipeline and all the clinical signs are looking good. Which means you have to start focusing on your launch strategy to ensure commercial success. You need to refine your list of potential opportunities and threats, and develop forecasts that will ensure the […]
Three Things we Learned in our “Taking the Pharma Industry Pulse” Webinar
One of the great things about working in the pharma industry is the opportunity to listen to very clever people talking about fascinating topics and the latest trends in the market. Events like BIO-Europe are brilliant for this, and there is always plenty to unpack after the panels, keynotes and fireside chats have ended. Our […]
CDMOs: A Paradigm Change for Pharma?
At the recent CPHI exhibition in a very wet Milan, you couldn’t move for booths expounding on the capabilities of the world’s manufacturing, services, packaging and ingredients players. Some of these companies formerly considered themselves to be Contract Research Organisations (CROs) or CMOs (Contract Manufacturing Organisations) but now proudly display the letters CDMO (Contract Development […]
